ロード中...
表皮生长因子受体突变细胞系H1650耐药机制探讨
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) overexpression and mutations were existed in more than 40% of the lung cancer, and it's the one of molecular targets in clinical treatment. But the EGFR tyrosine kinase inhibitors (TKI)-resistance is becoming a challenging clinic...
保存先:
| 出版年: | Zhongguo Fei Ai Za Zhi |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
中国肺癌杂志编辑部
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000043/ https://ncbi.nlm.nih.gov/pubmed/23249714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2012.12.02 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|